PMID- 10925367
OWN - NLM
STAT- MEDLINE
DCOM- 20000816
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 87
IP  - 5
DP  - 2000 Sep 1
TI  - Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small 
      cell lung cancer: a phase II study of the italian oncology group for clinical 
      research (GOIRC).
PG  - 724-7
AB  - The purpose of this study was to evaluate the activity and the toxicity of the 
      combination of gemcitabine with ifosfamide and cisplatin (GIP) in chemonaive 
      patients with advanced non small cell lung cancer (NSCLC). Eighty chemonaive 
      patients with Stage IIIB-IV NSCLC were treated with the combination of 
      gemcitabine 1 g/m(2) on Days 1 and 8, ifosfamide 2 g/m(2) on Day 1 and cisplatin 
      80 mg/m(2) on Day 2. Cycles were administered on an outpatient basis every 3 
      weeks. Hematologic toxicity was the main side effect; Grade III-IV 
      thrombocytopenia was observed in 54 (67%) patients and Grade III-IV leucopenia in 
      44 (55%) patients, with 4 episodes of febrile neutropenia and 1 toxic death. 
      Thirteen patients received platelet transfusions and 38 were transfused with 
      packed red cells. All patients were evaluable for response. The overall response 
      rate was 54% (95% confidence interval 43 to 65%) with 1 complete response. In 
      patients with Stage IIIB and IV disease, response rates were 58% and 52%, 
      respectively. Median time to progression was 40 weeks (range 0-114) and median 
      overall survival was 12 months (16.6 months for stage IIIB and 10.4 months for 
      stage IV). Median and minimum follow-up were 19 and 12 months, respectively. The 
      GIP combination shows a response rate and overall survival of clinical interest. 
      Hematologic toxicity was the main toxic effect, especially in patients with low 
      performance status. This regimen will be tested in a Phase III randomized trial.
CI  - Copyright 2000 Wiley-Liss, Inc.
FAU - Boni, C
AU  - Boni C
AD  - Medical Oncology Service, Arcispedale S. Maria Nuova, Reggio Emilia, Italy. 
      boni.corrado@asmn.re.it
FAU - Bisagni, G
AU  - Bisagni G
FAU - Savoldi, L
AU  - Savoldi L
FAU - Moretti, G
AU  - Moretti G
FAU - Rondini, E
AU  - Rondini E
FAU - Sassi, M
AU  - Sassi M
FAU - Zadro, A
AU  - Zadro A
FAU - De Pas, T
AU  - De Pas T
FAU - Franciosi, V
AU  - Franciosi V
FAU - Pazzola, A
AU  - Pazzola A
FAU - Vignoli, R
AU  - Vignoli R
FAU - Banzi, M C
AU  - Banzi MC
FAU - Pajetta, V
AU  - Pajetta V
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0W860991D6 (Deoxycytidine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - UM20QQM95Y (Ifosfamide)
RN  - GIP protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Deoxycytidine/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Ifosfamide/administration & dosage/adverse effects
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neutropenia/chemically induced
MH  - Thrombocytopenia/chemically induced
EDAT- 2000/08/05 11:00
MHDA- 2000/08/19 11:00
CRDT- 2000/08/05 11:00
PHST- 2000/08/05 11:00 [pubmed]
PHST- 2000/08/19 11:00 [medline]
PHST- 2000/08/05 11:00 [entrez]
AID - 10.1002/1097-0215(20000901)87:5<724::AID-IJC15>3.0.CO;2-N [pii]
PST - ppublish
SO  - Int J Cancer. 2000 Sep 1;87(5):724-7.